CaMKII activity is essential for improvement of memory-related behaviors by chronic rivastigmine treatment

Journal of Neurochemistry

Volumn 128, Issue 6, 2014, Pages 927-937

  Moriguchi, Shigeki ^a,b   Tagashira, Hideaki ^a   Sasaki, Yuzuru ^a   Yeh, Jay Z ^b   Sakagami, Hiroyuki ^c   Narahashi, Toshio ^b   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; CaMKII; long term potentiation; OBX mice; rivastigmine

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUTAMATE RECEPTOR 1; RIVASTIGMINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; BARNES MAZE TEST; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HIPPOCAMPAL CA1 REGION; IMMUNOBLOTTING; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RECOGNITION; REGULATORY MECHANISM; Y-MAZE TEST;

MUS;

ALZHEIMER'S DISEASE; CAMKII; LONG-TERM POTENTIATION; OBX MICE; RIVASTIGMINE;

ALZHEIMER DISEASE; ANIMALS; ANIMALS, OUTBRED STRAINS; CA1 REGION, HIPPOCAMPAL; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 4; CHOLINESTERASE INHIBITORS; DENERVATION; DISEASE MODELS, ANIMAL; LONG-TERM POTENTIATION; MALE; MEMORY; MEMORY DISORDERS; MICE; OLFACTORY BULB; PHENYLCARBAMATES;

EID: 84895927189     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12510     Document Type: Article

References (44)

1. Anand R., Gharabawi G., and, Enz A., (1996) Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J. Drug Dev. Clin. Pract. 8, 109-116.
2. Barria A., Muller D., Derkach V., Griffith L. C., and, Soderling T. R., (1997) Regulatory phosphorylation of AMPA-type glutamate receptor by CaM-KII during long-term potentiation. Science 276, 2042-2045.
3. Bliss T. V., and, Collingridge G. L., (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 31-39.
4. Corey-Bloom J., Anand R., and, Veach J., (1998) A randomised trial evaluating the efficacy and safety of Ena713 (rivastigmine tartrate), a new acetylChE inhibitor, in patients with mild to moderatory severe Alzheimer's disease. Int. J. Geriatr. Psychopharmacol. 1, 55-65.
5. Corwin J., Serby M., Conrad P., and, Rotrosen J., (1985) Olfactory recognition deficit in Alzheimer's disease and Parkinsonian dementias. IRCS Med. Sci. 13, 260.
6. 2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc. Natl Acad. Sci. USA 96, 3269-3274.
7. Fukunaga K., and, Miyamoto E., (2000) A working model of CaM Kinase II activity in hippocampal long-term potentiation and memory. Neurosci. Res. 38, 3-17.
8. 2+/ calmodulin-dependent protein kinase II. J. Bio. Chem. 268, 7863-7867.
9. 2+/calmodulin-dependent protein kinase II and its endgeneous substrates in the induction of long term potentiation. J. Bio. Chem. 270, 6119-6124.
10. 2+/calmodulin-dependent protein kinase II-dependent long-term potentiation in the rat suprachiasmatic nucleus and its inhibition by melatonin. J. Neurosci. Res. 70, 799-807.
11. 3H] glutamate binding. J. Neurochem. 48, 543-551.
12. Han F., Shioda N., Moriguchi S., Qin Z. H., and, Fukunaga K., (2008) The vanadium (IV) compound rescues septo-hippocampal cholinergic neurons from neurodegeneration in olfactory bulbectomized mice. Neuroscience 151, 671-679.
13. Hozumi S., Nakagawasai O., Tan-No K., Niijima F., Yamadera F., Murata A., Arai Y., Yasuhara H., and, Tadano T., (2003) Characteristics of chages in cholinergic function and inmairment of learning and memory-related behavior induced by olfactory bulbectomy. Behav. Brain Res. 138, 9-15.
14. 2+/calmodulin-dependent protein kinase type Gr in rat cerebellar cortex. Proc. Natl Acad. Sci. USA 88, 2850-2853.
15. Kang H., Sun L. D., Atkins C. M., Soderling T. R., Wilson M. A., and, Tonegawa S., (2001) An important role of neural activity-dependent CaMKIV signaling in the consolidation of long-term memory. Cell 106, 771-783.
16. Kasahara J., Fukunaga K., and, Miyamoto E., (2001) Activation of calcium/calmodulin-dependent protein kinase IV in long term potentiation in the rat hippocampal CA1 region. J. Biol. Chem. 276, 24044-24050.
17. Kelly J. P., Wrynn A. S., and, leonard B.E., (1997) The olfactory bulbectomized rat as a model of depression: An update. Pharmacol. Ther. 74, 299-316.
18. Koss E., (1986) Olfactory dysfunction in Alzheimer's disease. Dev. Neuropsychol. 2, 89-99.
19. Laemmli U. K., (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
20. Li M., Zhang D. Q., Wang X. Z., and, Xu T. J., (2011) NR2B-containing NMDA receptors promote neural progenitor cell proliferation through CaMKIV/CREB pathway. Biochem. Biophys. Res. Commun. 411, 667-672.
21. Lisman J., Schulman H., and, Cline H., (2002) The molecular basis of CaMKII function in synaptic and behavioral memory. Nat. Rev. Neurosci. 3, 175-190.
22. 2+/calmodulin-dependent protein kinase II and mitogen-activated protein kinase activation in hippocampal long-term potentiation. J. Neurosci. 19, 8292-8299.
23. Lledo P. M., Hjelmstad G. O., Mukherji S., Soderling T. R., Malenka R. C., and, Nicoll R. A., (1995) Calcium/calmodulin-dependent kinase II and long-term potentiation enhance synaptic transmission by the same mechanism. Proc. Natl Acad. Sci. USA 92, 11175-11179.
24. Malenka R. C., and, Nicoll R. A., (1999) Long-term potentiation-a decade of progress? Science 285, 1870-1874.
25. Matsuno N., Yamasaki N., Ohira K., Takao K., Toyama K., Eguchi M., Yamaguchi S., and, Miyakawa T., (2009) Neural activity changes underlying the working memory deficit in alpha-CaMKII heterozygous knockout mice. Front. Behav. Neurosci. 3, 1-10.
26. Miyano O., Kameshita I., and, Fijisawa H., (1992) Purification and characterization of a brain-specific multifunctional calmodulin-dependent protein kinase from rat cerebellum. J. Biol. Chem. 267, 1198-1203.
27. Moriguchi S., Han F., Nakagawasai O., Tadano T., and, Fukunaga K., (2006) Decreased calcium/calmodulin-dependent protein kinase II and protein kinase C activities mediate impairment of hippocampal long-term potentiation in the olfactory bulbectomized mice. J. Neurochem. 97, 22-29.
28. Moriguchi S., Han F., Shioda N., Yamamoto Y., Nakajima T., Nakagawasai O., Tadano T., Yeh J. Z., Narahashi T., and, Fukunaga K., (2009) Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice. J. Neurochem. 110, 170-181.
29. Moriguchi S., Yamamoto Y., Ikuno T., and, Fukunaga K., (2011) Sigma-1 receptor stimulation by dehydroepiandrosterone ameliorates cognitive impairment through activation of CaM kinase II, protein kinase C and extracellular signal-regulated kinase in olfactory bulbectomized mice. J. Neurochem. 117, 879-891.
30. Moriguchi S., Tanaka T., Narahashi T., and, Fukunaga K., (2013) Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine binding site of N-methyl-D-aspartate receptor. Hippocampus 23, 942-951.
31. Patil S. S., Sunyer B., Hoger H., and, Lubec G., (2009) Evaluation of spatial memory of C57BL/6J and CD1 mice in the Barnes maze, the Multiple T-maze and in the Morris water maze. Behav. Brain Res. 198, 58-68.
32. Prickaerts J., Van Staveren W. C. G., Sik A., Markerink-Van Ittersum M., Niewohner U., Van der Staay F. J., Blokland A., and, De vente J., (2002) Effects of two selective phosphodiesterase type5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 113, 349-359.
33. Rosler M., Anand R., Cicin-Dain A., Gauthier S., Agid Y., Dal-Bianco P., Stahelin H. B., Hartman R., and, Gharabawi M., (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br. Med. J. 318, 633-638.
34. Serby M., Corwin J., Conrad P., and, Rotrosen R. P., (1985) Olfactory dysfunction in Alzheimer's disease and Parkinson's disease. Am. J. Psychiatry 142, 781-782.
35. Soderling T. R., and, Derkach V. A., (2000) Postsynaptic protein phosphorylation and LTP. Trends Neurosci. 23, 75-80.
36. Song N., Nakagawa S., Izumi T., Toda H., Kato A., Boku S., Inoue T., Sakagami H., Li X., and, Koyama T., (2013) Involvement of CaMKIV in neurogenic effect with chronic fluoxetine treatment. Int. J. Neuropsychopharmacol. 16, 803-812.
37. Takao K., Tanda K., Nakamura K., et al,. (2010) Comprehensive behavioral analysis of calcium/calmodulin-dependent protein kinase IV knockout mice. PLoS ONE 5, e9460.
38. Wang Y.-J., Chen G.-H., Hu X.-Y., Lu Y.-P., Zhou J.-N., and, Liu R. Y., (2005) the expression of calcium/calmodulin-dependent protein kinase II-a in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology. Brain Res. 1031, 101-108.
39. Warner M. D., Peabody C. A., Flattery J. J., and, Tinklenberg J. R., (1986) Olfactory deficits and Alzheimer's disease. Biol. Psychiatry 2, 116-118.
40. Weinstock M., Razin M., Chorev M., and, Enz A., (1994) Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylChE inhibitors. J. Neural Transm. Suppl. 43, 219-225.
41. Wu G. Y., Deisseroth K., and, Tsien R. W., (2001) Activity-dependent CREB phosphorylation: convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway. Proc. Natl Acad. Sci. USA 98, 2808-2813.
42. Xia Z., and, Storm D. R., (2005) The role of calmodulin as a signal integrator for synaptic plasticity. Nat. Rev. Neurosci. 6, 267-276.
43. Yamagata Y., (2003) New aspects of neurotransmitter release and exocytosis: dynamic and differential regulation of synapsin I phosphorylation by acute neuronal excitation in vivo. J. Pharmacol. Sci. 93, 22-29.
44. Yamasaki N., Maekawa M., Kobayashi K., et al,. (2008) Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol. Brain 1, 6.